-
Clinical Trials & Development4 weeks agoMicrobiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age
Researchers analyzing pre-treatment stool samples from 1,364 cancer patients across cancer types, stages, and treatments discovered that adults aged 50 years or younger with colorectal and...
-
Clinical Trials & Development4 weeks agoLilly’s Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1C Reduction, Underscoring its Potential Promise for People with Obesity and Type 2 Diabetes
INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2,...
-
Clinical Trials & Development4 weeks agoCDER Patient-Focused Drug Development
Patient-focused drug development (PFDD) is a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development...
-
Clinical Trials & Development1 month agoKodiak skyrockets on positive study data for 2 eye drugs
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
-
Clinical Trials & Development1 month agoKodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
-
Clinical Trials & Development1 month agoSTAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better
-
Clinical Trials & Development1 month agoRoche drops muscle-sparing obesity antibody after flunked interim analysis
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.
-
Clinical Trials & Development1 month agoDaiichi Sankyo, MSD withdraw cancer drug application
The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which...
-
Clinical Trials & Development1 month agoMirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space...
-
Clinical Trials & Development1 month ago
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria
PALO ALTO, Calif., Sept. 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics,...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
